Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study. [electronic resource]
Producer: 20191209Description: 772-776 p. digitalISSN:- 1524-4733
- Cladribine -- administration & dosage
- Confounding Factors, Epidemiologic
- Disability Evaluation
- Disease Progression
- Drug Substitution
- Humans
- Immunosuppressive Agents -- administration & dosage
- Models, Statistical
- Multiple Sclerosis, Relapsing-Remitting -- diagnosis
- Patient Dropouts
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.